Market access in Brazil: All eyes on Spinraza
Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil?
In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde (SUS). This is the first agreement in Brazil to include a risk-sharing model, in which the government only pays for the drug if there is improvement in the patient's health. In a country where it typically takes years for innovative pharmaceutical products to be reimbursed in the public sector, manufacturers wishing to obtain market access for their products in Brazil will be watching this example closely to see how it plays out.
Men vs women in emerging markets
Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging markets.
While a wide-range range of societal and economic factors influence health outcomes, one of the most significant factors is gender. In addition to overall morbidity and mortality, certain health issues are more commonly associated with one gender. But while biology plays a role, it is predominantly the way in which society structures and shapes men’s and women’s lives that result in health inequalities. Gender norms, roles and expectations vary between cultures, particularly in emerging markets, and affect the way in which health care is accessed. Our latest interactive infographic compares the lives of men vs women in the BRIC emerging markets, and explores how societal factors impact their respective health outcomes.
Nutrition Market in Brazil: Growth Against the Odds
Published in eyeforpharma June 2017 by Marc Yates
Until the recession of 2014, Brazil saw a sustained period of strong growth in the functional foods and nutritional supplements market, albeit from a low base. The wealth gap was closing and a burgeoning, better-educated middle class with a rising disposable income was increasingly interested in nutrition products, both as lifestyle accessory and aid to healthier, longer lives.
Interactive infographic: LATAM
An overview of the six most-commonly researched, largest pharma markets in Latin America
The LATAM region's largest markets of Argentina, Brazil, Chile, Colombia, Mexico and Venezuela, is home to more than 460 million people and is a key global growth region. With pharmaceutical sales of more than $64bn, it is an attractive market for pharma, however it is also one in which each market differs in terms of opportunities and challenges.
HCV LATAM infographic
Hepatitis C virus (HCV) is well recognised as a worldwide problem with approximately 150 million chronic carriers. If left untreated HCV becomes a chronic health problem putting a huge strain on national healthcare resources. Within Latin America studies suggest that around 4.6 million people are currently infected with chronic HCV.
Click here to view our latest infographic, in which we provide an introduction to the HCV LATAM patient.
Find out more about our experience in emerging markets »
Sign up to receive Rapport Rapport is our e-newsletter and online resource for sharing our expertise and experience in global healthcare market research. Sign up here »